PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Inclusion Criteria: * Histological diagnosis of prostate cancer * Evidence of metastatic disease by radiologic criteria * Bone scan within 4 weeks of starting therapy * Creatinine within 2 weeks of registration, calculated creatinine clearance \> 60ml/min. * Minimum life expectancy of 6 months * Willingness to have pre-therapy PET scans performed within 2 weeks after registration and post therapy PET scan performed within 1 week after dose of Zometa (a total of 3 PET scans required) * Calculated creatinine clearance \> 50ml/min. * No prior Zoledronate therapy * Patients must have disease progression despite testosterone suppression (level\<50ng/ml); progression can be by rising PSA ( at least 2 values at least 2 weeks apart) or by new lesions on scans or progression of existing lesions on CT scan. * No concomitant systemic therapy for metastatic prostate cancer is allowed except LHRH analogue should be continued if necessary to maintain testosterone suppression. * No concomitant radiation therapy * Prior RT is allowed if completed at least 2 weeks prior to registration. * Presence of measurable or evaluable disease * If RT has been administered, disease outside the RT port is required. * Willingness to sign informed consent. * Registration and willingness to sign informed consent for separate PET protocol 2335 that describes the PET scan procedure. * Patients must have good oral hygiene which includes having a recent dental evaluation Exclusion Criteria: * Patients who are unable to swallow * Patients with dental cavities that are likely to need dental extraction or root canal treatment as management